Gorden Redlich

This inventor holds 39 USPTO granted patents and 10 published patent applications, plus 4 CIPO patents and 22 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Bayer Pharma Aktiengesellschaft, Bayer Intellectual Property Gmbh, Adverio Pharma Gmbh. Active years: 2013-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gorden Redlich. Retrieved from https://idiyas.com/inventor/gorden-redlich

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 39 (Patent Applications = 10)

% Patents Active = 48.7

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 22 (Patent Applications = 35)

Average Co-Inventor Count = 11.0

ph-index = 11

Forward Citations = 355(Granted Patents)

Company Filing History:

22 out of 386

Bayer Pharma Aktiengesellschaft

patents

17 out of 721

Bayer Intellectual Property Gmbh

where one patent can have more than one assignee

Years Active: 2013-2024

Loading Chart...

Areas of Expertise:

Pyrazolopyridines

Imidazo Derivatives

Prodrugs

Tetrahydroquinolines

Triazines

Pyridinecarboxamides

Aza Heterocycles

Cardiovascular Treatment

Carbamates

Fluoroalkyl Compounds

Bicyclic Compounds

Fused Imidazoles

39 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12064429 - Substituted 5-fluoro-1H-pyrazolopyridines and their use (2024-08-20),

2. 11439642 - Substituted 5-fluoro-1H-pyrazolopyridines and their use (2022-09-13),

3. 10961221 - Substituted piperidinyl tetrahydroquinolines (2021-03-30),

4. 10736896 - Substituted 5-fluoro-1H-pyrazolopyridines and their use (2020-08-11),

5. 10662185 - Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use (2020-05-26),

6. 10323020 - Substituted piperidinyl tetrahydroquinolines (2019-06-18),

7. 10052312 - Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use (2018-08-21),

8. 10035818 - Polyethylene glycol based prodrug of adrenomedullin and use thereof (2018-07-31),

9. 9993476 - Substituted 5-flouro-1H-pyrazolopyridines and their use (2018-06-12),

10. 9944621 - Substituted piperidinyl tetrahydroquinolines (2018-04-17),

11. 9776997 - 3-aryl-substituted imidazo[1,2-A]pyridines and their use (2017-10-03),

12. 9771360 - Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their use (2017-09-26),

13. 9688699 - 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines (2017-06-27),

14. 9649363 - Polyethylene glycol based prodrug of adrenomedullin and use thereof (2017-05-16),

15. 9624214 - Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use (2017-04-18),

Title: Gorden Redlich - Innovator in Pharmaceutical Patents

Introduction

Gorden Redlich is a prominent inventor based in Bochum, Germany, known for his immense contributions to the field of pharmaceuticals with a total of 39 patents to his name. His innovative work primarily focuses on developing novel compounds aimed at treating various diseases, particularly cardiovascular disorders.

Latest Patents

Among his latest advancements are the patents filed for substituted 5-fluoro-1H-pyrazolopyridines. These inventions relate to novel compounds that are useful in the treatment and prophylaxis of diseases. The patents detail the processes for their preparation and highlight their potential in producing medicaments specifically aimed at addressing cardiovascular disorders.

Career Highlights

Throughout his career, Gorden Redlich has worked with notable companies, including Bayer Pharma Aktiengesellschaft and Bayer Intellectual Property GmbH. His tenure at these organizations has provided him with the platform to develop and patent crucial innovations that contribute to modern medicine.

Collaborations

Redlich has collaborated with distinguished professionals in the industry, including Frank Wunder and Johannes-Peter Stasch. These collaborations underscore the importance of teamwork in the realm of innovation and development in pharmaceuticals.

Conclusion

Gorden Redlich stands out as a notable inventor whose contributions continue to shape the future of medical treatment, especially in cardiovascular health. With a strong track record of patents and a collaborative spirit, he remains a significant figure in the pharmaceutical industry.

Profile summary based on public USPTO records.